strong perform due growth across segment
maintain buy rate abbott upgrad tp
previous provid upsid potenti
deriv estim base
forward price-to-earnings multipl ep
estim top-lin revenu grow
estim base follow factor strong growth
across segment signific advanc pipelin
signific improv balanc sheet
abbott gave outstand perform
growth revenu near revenu
estim adjust ep grew
near estim
establish epd sale grew led
double-digit growth india china
world-wide sale increas report basi
organ basi due continu strong adopt alin
abbott nutrit busi increas
world-wide sale perform led strong growth
ensur abbott market-lead complet balanc nutrit
brand glucerna abbott market-lead diabetes-specif
mn except ep crispidea name tickerabtstock ratingbuyunchangedindustri viewoverweightpositivepric week week volum volum ep gin gin ttm per share growth profit ttm ttm incom ttm earn growth yoy n/acrispideaakansha ch
incom statement
non-
per share item
product perform develop
valuat consensu perform
abbott gener strong oper cash flow
paid debt abbott
return sharehold form dividend
decemb announc increas quarterli
octob abbott receiv fda approv
heartmat left ventricular assist devic destin
januari abbott announc fda approv
enabl new cathet design help physician
accur effect treat atrial fibril form
electrophysiolog growth led heart
map ablat portfolio year
advanc product portfolio area launch
advisor hd cathet creat highli detail map
heart
current price-to-earnings trade
price-to-earnings trail
sinc august due strong growth stock price
price-to-earnings averag price-to-earnings
expect forward price-to-earnings multipl
recommend buy rate abbott due strong
growth busi advanc pipelin
expect revenu grow
stock price histori date high obsolet date obsolet move move share statist averag volum averag volum share held held share short short float n/a share short prior month error dividend split forward annual dividend forward annual dividend trail annual dividend trail annual dividend year averag dividend pay-out dividend date may ex-dividend date apr last split factor new per last split date jan inform abbott laboratori march
incom statement
non-
per share item
product perform develop
valuat consensu perform
non- reconcili refer page
incom statement total gross research sale gener total oper oper interest incom incom provis incom net incom continu net incom discontinu net incom avail common weight averag share estim annual actual annual actual quarterli march
 market account receivable- total prepaid current assets- total current build machineri furnitur total fix non-curr defer incom non-curr total non-curr total equiti liabilitiesaccount accru current liabilities- total current long-term defer incom taxes- non-curr minor interest total non-curr liabilities- total liabilities- prefer stock equity- common stock addit paid-in retain treasuri total total total liabil stock actual annual actual quarterli balanc sheet item abbott laboratori march
net cash oper activ increas due higher segment oper earn
continu improv work capit manag time pension contribut lower
net cash use invest activ compar
net cash use financ activ compar
defer incom taxes- oper increas decreas increas decreas current assets- decreas increas decreas increas current liabilities- decreas increas work capital- non- net continu net discontinu operations- net total oper invest activitiessal properti plant equipment- purchas properti plant acquisitions- net invest financ activitiesissu issuanc capit stock- repurchas capit payment financ charg net- discontinu financ activities- net financ net floweffect exchang rate net chang begin end march
abbott deliv strong result year signific advanc
pipelin improv balanc sheet
compar
total revenu increas compar
organ sale increas
diagnost achiev sale acquir late
therefor includ organ sale exchang unfavor y/i
impact sale
increas
compar
total revenu increas compar
total intern revenu increas
compar
cog decreas compar
amort intang asset decreas
compar gross profit increas
compar
 expens decreas compar
sg expens increas
compar oper incom increas
compar
interest expens net declin compar
incom compar
incom tax provis compar
net earn compar net loss
ep compar
non-gaap ep compar
total revenu increas compar
total revenu increas
compar total intern revenu increas
compar sale increas
driven higher structur heart electrophysiolog neuromodul
cog increas compar
gross margin compar increas
reflect lower inventori step-up amort relat st jude medic
aler acquisit margin improv variou busi partial off-set
higher intang amort expens
amort intang asset increas
compar expens increas
compar increas expens due higher
spend variou project partial off-set lower restructur
compar
compar
sg expens increas compar
increas due impact acquisit
aler busi octob well higher spend drive continu
growth market expans variou busi partial off-set lower
oper incom increas compar
interest expens net compar
incom compar
net earn increas compar
gaap ep compar non-gaap ep
compar
decreas
report
basi
includ unfavor
effect foreign
exchang increas
organ basi
abbott oper differ segment establish pharmaceut
product nutrit diagnost medic devic total revenu
report segment increas compar
segment revenu total revenu
establish pharmaceut sale decreas
report basi includ unfavor effect
foreign exchang increas organ basi total
revenu increas
emerg market includ india brazil russia china along
sever addit emerg countri repres attract
long-term growth opportun abbott brand gener product
sale key emerg market decreas
report basi includ unfavor effect foreign exchang
increas organ basi sale key emerg market
increas report basi organ basi
led double-digit growth india china
sale increas report basi
organ basi sale increas report
basi organ basi
world-wide revenu nutrit product decreas
report basi compar
sale includ unfavor effect foreign exchang
increas organ basi total revenu increas
total revenu decreas
compar previou year quarter total revenu increas
total intern revenu decreas
compar previou year quarter total intern revenu
increas
world-wide pediatr nutrit revenu increas
compar previou year quarter includ unfavor
effect foreign exchang increas organ basi total
revenu increas compar prior-year
world-wide revenu
decreas
report basi
compar
increas
compar previou
year quarter
total revenu increas
compar previou year quarter total revenu
increas compar prior-year period
total intern revenu decreas report basi
compar previou year quarter total revenu
increas compar prior-year period
perform quarter led above-market growth
strong growth across sever market asia latin america includ
china vietnam mexico
total revenu decreas compar
previou year quarter total revenu increas
compar prior-year period world-wide sale perform
led strong growth ensur abbott market lead complet
balanc nutrit brand glucerna abbott market-lead diabet
total revenu declin
compar previou year quarter total revenu
decreas compar prior-year period
total intern revenu increas report basi
compar previou year quarter total revenu
increas compar prior-year period
revenu
increas
compar previou
year quarter
decreas
compar previou
year quarter
revenu increas
compar
previou year
increas
compar
previou year
world-wide diagnost revenu increas
compar previou year quarter revenu increas
organ basi total revenu increas
compar prior-year period increas sale driven above-
market growth laboratori intern
diagnost product revenu increas
compar previou year quarter total revenu
 increas compar prior-year
diagnost product intern revenu increas
compar previou year quarter total intern
revenu increas compar prior-
laboratori diagnost revenu increas
compar previou year quarter includ
unfavor effect foreign exchang increas
organ basi total revenu increas compar
prior-year period
increas reflect above-market growth intern
abbott see continu strong adopt alin abbott famili
innov highli differenti diagnost instrument
total revenu increas
compar previou year quarter total revenu
increas
total intern revenu increas
compar previou year quarter total revenu increas
compar prior-year period
increas
compar previou
year quarter
point diagnost
revenu decreas
compar
previou year
world-wide molecular diagnost revenu increas
compar previou year quarter includ
unfavor effect foreign exchang increas organ
basi total revenu increas compar
prior-year period
world-wide sale led growth infecti diseas test abbott
core area focu molecular diagnost market
total revenu increas
compar previou year quarter total revenu decreas
compar prior year period
total intern revenu increas
compar previou year quarter total intern revenu
increas
point diagnost
point diagnost revenu decreas
compar previou year quarter includ unfavor
effect foreign exchang decreas organ basi total
revenu increas compar prior
total revenu decreas
compar previou year quarter total revenu
declin
total intern revenu decreas
compar previou year quarter total intern revenu
increas compar prior-year
report
basi
compar
previou year
rapid diagnost revenu increas
compar previou year quarter total revenu
growth led infecti diseas cardiometabol test
total revenu
total intern revenu
world-wide medic devic sale increas report basi
compar previou year quarter
organ basi sale increas total revenu increas
compar prior-year period
medic devic revenu increas
compar previou year quarter total revenu
 increas compar prior-year period
medic devic intern revenu increas
compar previou year quarter total intern
revenu increas compar prior-year
period
cardiovascular neuromodul
cardiovascular neuromodul revenu increas
compar previou year quarter total revenu
increas compar prior-year period
cardiovascular
revenu increas
compar
previou year
cardiovascular neuromodul
cardiovascular
revenu
increas
compar previou
year quarter
cardiovascular neuromodul revenu increas
compar previou year quarter total
revenu increas compar prior-year
period
cardiovascular neuromodul intern revenu increas
compar previou year quarter
total intern revenu increas
revenu increas
compar
previou year
electrophysiolog revenu increas
compar previou year quarter total revenu increas
growth led strong perform cardiac
map ablat cathet januari abbott announc fda
approv tacticath contact forc ablat cathet sensor enabl
electrophysiolog revenu increas
total revenu increas
total intern revenu increas
increas
structur heart revenu increas
compar previou year quarter total revenu increas
structur heart revenu increas
total revenu increas
total intern revenu increas total
intern revenu increas
growth structur heart driven sever product area across
abbott broad portfolio includ amplatzertm pfo occlud
cardiovascular neuromodul
revenu declin
decreas
rhythm manag revenu declin
total revenu decreas total revenu
 decreas total revenu
decreas total intern revenu declin
total intern revenu declin
heart failur increas increas
total revenu decreas
decreas total
intern revenu increas increas
vascular revenu decreas increas
total revenu decreas
decreas total
intern revenu increas increas
neuromodul revenu decreas
increas total revenu increas
increas total
intern revenu decreas increas
increas
compar previou
year quarter
revenu increas
compar
previou year
diabet revenu increas
compar previou year quarter total revenu increas
compar prior-year period
growth led rapid market uptak freestyl libr abbott
revolutionari sensor base continu glucos monitor system
remov need routin fingerstick peopl diabet
total revenu increas
increas total intern revenu
increas increas
abbott expect adjust ep rang organ
sale growth expect base current rate
would expect exchang unfavor impact
report sale vast major impact expect occur
forecast adjust gross margin ratio sale
forecast adjust invest sale adjust sg
expens sale
forecast net interest expens non-oper incom
around forecast adjust tax rate
abbott forecast adjust ep forecast
organ sale growth current rate would expect
exchang neg impact around sale
forecast adjust gross margin ratio sale adjust
invest sale adjust sg expens sale
ep rang
organ
sale growth
expect
ep
organ sale growth
abbott deliv strong perform growth revenu
adjust ep increas ep
electrophysiolog growth led heart map ablat
portfolio year advanc product portfolio area
launch advisor hd cathet creat highli detail map
heart
structur heart landmark year busi achiev
double-digit growth perhap importantli announc clinic trial result
mitraclip market lead devic minim invas repair
mitral valv demonstr improv surviv clinic outcom patient
preval form heart diseas
diabet achiev growth growth led
freestyl libr achiev global sale increas
versu prior year
octob abbott receiv fda approv heartmat left ventricular
assist devic destin long-term use therapi januari abbott
announc fda approv tacticath contact forc ablat cathet
sensor enabl new cathet design help physician accur
effect treat atrial fibril form irregular heartbeat
anoth outstand year abbott achiev strateg
financi object despit challeng currenc shift year top
tier perform demonstr strength strategi portfolio
execut abbott forecast continu strong organ sale
growth double-digit ep growth
year
advanc product
portfolio
electrophysiolog
launch advisor
hd cathet
map heart
approv
non- reconcili
non- reconcili
non- reconcili
incom statement
non-
per share item
product perform develop
valuat consensu perform
gross margin increas compar due decreas cog
oper margin increas compar due decreas expens
y/i revenu growth compar
net margin increas compar due declin tax rate
ratio revenu margin margin inc margin rate margin turnov averag asset leverag averag equiti year averag averag averag year averag averag averag year averag averag averag growth growth ex sale /sale /net incom ratio profit marginsprofitabilityrevenu growth oper incom growthep growth abbott laboratori march
mrqgross mrqcog mrqoper mrqnet mrqr mrqsg sale abbott laboratori march
invest flow
sale
mrqyoy growth revenu growthoper incom growthep mrqfinanci mrqreturn mrqreturn mrq ratio growth yoy oper growth yoy free growth mrqcapex salescap ex salesfre /sale abbott laboratori march
per share item ratio
fiscal per ebitda per ebit per earn per share ep ep free flow per dividend per book valu per tangibl book per month end stock month end stock equiti return asset return invest capit return capit joel greenblatt debt gross margin oper margin net margin total equiti total lt debt total asset dividend pay-out day sale day account day convers inventori cog inventori tax rate net incom net incom net net margin prefer dividends- annual itemsquarterli item abbott laboratori march
balanc sheet item
outstand equival market debt common stock- prefer stock- purchas properti plant sale properti plant equipment- purchas sale purchas sale issuanc stock- repurchas net issuanc prefer stock- net issuanc net chang capit free march
current price-to-earnings trade price-to-earnings trail
sinc august due strong growth stock price price-to-earnings
averag price-to-earnings expect forward price-to-earnings multipl
incom statement
non-
per share item
product perform develop
valuat consensu perform
breakdown share held share held float held institut hold mutual fund holdersholdersharesd report outvaluevanguard total stock market invest compani vanguard growth fund america amcap spdr etf vanguard institut fund-institut vanguard specialized-health capit world growth incom vanguard specialized-dividend appreci abbott laboratori march
developmentsabbott latest diagnost technolog alin select region medic laboratori inc deliv benefit hospit patientsmarch region medic laboratori inc rml use compani advanc technolog alin ci-seri conduct diagnost test million patient rml part ascens network largest non-profit health system perform diagnost test patient hospit system intexa wisconsin oklahoma kansasand tennesse abbott novo nordisk enter partnership provid integr digit solut peopl diabet use insulinfebruari novo nordisk announc non-exclus partnership integr insulin dose data novo nordisk pre-fil durabl connect pen directli digit health tool compat freestyl libr system freestyl librelinkii mobil app libreviewiii cloud-bas system partnership reflect compani commit make diabet manag easier connect key technolog continu glucos monitor cgm connect insulin pen abbott introduc world sensit diagnost test determin hbsag acceler hepat carefebruari announc receiv ce mark world sensit rapid diagnost test detect hepat surfac antigen determin hbsag test use serum plasma whole blood highli sensit easy-to-us rapid later flow test enabl identif viru facilit linkag care everi healthcar set abbott acquir cephea valv inc januari announc exercis option purchas cephea valv technolog inc privat held medic devic compani develop less-invas heart valv replac technolog peopl mitral valv diseas financi term disclos abbott provid capit secur option purchas cephea march
incom statement
non-
per share item
product perform develop
valuat consensu perform
compar
roa roi roe
ttm
actual vs price-to-earnings ratio ttm price-to-earnings high last yr price-to-earnings last yr beta price sale ttm price book mrq price ttm price free ttm errorerrorerror own dividend yield dividend yield year average dividend year growth rate pay-out ratio ttm sale mrq vs qtr yr sale ttm vs ttm yr sale yr growth rate sale yr growth rate ep mrq vs qtr yr ep ttm vs ttm yr ep yr growth rate ep yr growth rate capit spend yr growth rate lt debt equiti mrq total debt equiti mrq interest coverag ttm gross margin ttm gross margin yr average ebitd margin ttm ebitd yr average oper margin ttm oper margin yr average pre-tax margin ttm pre-tax margin yr average net profit margin ttm net profit margin yr average effect tax rate ttm effect tax rate yr average return asset ttm return asset yr average return invest ttm return invest yr average return equiti ttm return equiti yr average revenue/employe ttm net income/employe ttm receiv turnov ttm inventori turnov ttm asset turnov ttm manag effect effici performancevalu ratio dividend growth rate ratio profit abbott laboratori march
consensu view analyst trend stock
forecast
compar
abbott forward price-to-earnings
compar
annual usdgrowth high day day day estim avgfive-year growth forecast comparisonabtindustri avg avgprice/earn yield march
consensu view analyst trend stock
averag earn estim
current qtr
next qtr
sale growth estim current
qtr
next qtr
averag revenu estim
current qtr
estimatescurr analyst estimatethi estim estimatepast ep growthprice/earningsobsoleteobsoleteobsoleteobsoletepeg ratioobsoleteobsoleteobsoleteobsoleteconsensu ep day day day day ep last last daysn/an/an/an/adown last dayserrorerrorerrorerrordown last dayscurr growth ratescurr surprisescurr march
incom statement
non-
per share item
product perform develop
valuat consensu perform
stock price shown upward trend past due strong growth compani
stock surg march gave return past
stock price movement show upward trend last one year surg
stock gave return last one year rang stock
stock price movement shown upward trend gave return past
growth stock price due growth busi advanc pipelin
abbott deliv strong perform due continu growth across segment
recommend buy rate abbott tp estim base abt
perform variou acquisit launch new product year
crispidea financi inform servic firm focus provid equiti research portfolio manag
person wealth manag brokerag servic inform servic side provid commun
consult research servic host ofclient
crispidea track limit number compani sector strive provid qualiti insight straight
forward analysi object creat long-term wealth moder low risk crispidea leverag
larg number in-hous extern expert oper within industri strong financi oper
strateg background
detail visit www crispidea com orcontact
